JP2025131696A5 - - Google Patents
Info
- Publication number
- JP2025131696A5 JP2025131696A5 JP2025093006A JP2025093006A JP2025131696A5 JP 2025131696 A5 JP2025131696 A5 JP 2025131696A5 JP 2025093006 A JP2025093006 A JP 2025093006A JP 2025093006 A JP2025093006 A JP 2025093006A JP 2025131696 A5 JP2025131696 A5 JP 2025131696A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- binding domain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944589P | 2019-12-06 | 2019-12-06 | |
| US62/944,589 | 2019-12-06 | ||
| US202063055085P | 2020-07-22 | 2020-07-22 | |
| US63/055,085 | 2020-07-22 | ||
| US202063057769P | 2020-07-28 | 2020-07-28 | |
| US63/057,769 | 2020-07-28 | ||
| JP2022533414A JP7693672B2 (ja) | 2019-12-06 | 2020-12-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| PCT/US2020/063395 WO2021113701A1 (en) | 2019-12-06 | 2020-12-04 | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533414A Division JP7693672B2 (ja) | 2019-12-06 | 2020-12-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025131696A JP2025131696A (ja) | 2025-09-09 |
| JP2025131696A5 true JP2025131696A5 (https=) | 2025-10-30 |
Family
ID=74106148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533414A Active JP7693672B2 (ja) | 2019-12-06 | 2020-12-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| JP2025093006A Pending JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533414A Active JP7693672B2 (ja) | 2019-12-06 | 2020-12-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11919965B2 (https=) |
| EP (1) | EP4069373A1 (https=) |
| JP (2) | JP7693672B2 (https=) |
| KR (1) | KR20220110510A (https=) |
| CN (1) | CN114929343B (https=) |
| AU (1) | AU2020398167A1 (https=) |
| CA (1) | CA3160352A1 (https=) |
| IL (1) | IL293288A (https=) |
| MX (1) | MX2022006714A (https=) |
| WO (1) | WO2021113701A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023524875A (ja) | 2020-05-11 | 2023-06-13 | ヤンセン バイオテツク，インコーポレーテツド | 多発性骨髄腫を治療するための方法 |
| MX2024005392A (es) * | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117886939B (zh) * | 2023-12-15 | 2024-07-26 | 康众(广东)生物医药有限公司 | 一组抗bcma的纳米抗体及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025240287A1 (en) * | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
| WO2026059923A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| WO2026059917A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| LT3394103T (lt) * | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| IL313507A (en) * | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY199468A (en) * | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| MD3823665T2 (ro) * | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3132587A1 (en) * | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
-
2020
- 2020-12-04 CN CN202080090951.6A patent/CN114929343B/zh active Active
- 2020-12-04 AU AU2020398167A patent/AU2020398167A1/en active Pending
- 2020-12-04 CA CA3160352A patent/CA3160352A1/en active Pending
- 2020-12-04 WO PCT/US2020/063395 patent/WO2021113701A1/en not_active Ceased
- 2020-12-04 JP JP2022533414A patent/JP7693672B2/ja active Active
- 2020-12-04 KR KR1020227021340A patent/KR20220110510A/ko active Pending
- 2020-12-04 IL IL293288A patent/IL293288A/en unknown
- 2020-12-04 EP EP20834037.2A patent/EP4069373A1/en active Pending
- 2020-12-04 US US17/112,564 patent/US11919965B2/en active Active
- 2020-12-04 MX MX2022006714A patent/MX2022006714A/es unknown
-
2024
- 2024-02-01 US US18/429,887 patent/US20250051466A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093006A patent/JP2025131696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025131696A5 (https=) | ||
| JP2024038003A5 (https=) | ||
| JP2024109678A5 (https=) | ||
| JP2022191301A5 (https=) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2023002562A5 (https=) | ||
| JP2021532170A5 (https=) | ||
| JP2015514110A5 (https=) | ||
| JP2021521843A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2023505218A5 (https=) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2013542194A5 (https=) | ||
| JP2023093753A5 (https=) | ||
| JP2015535828A5 (https=) | ||
| NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
| JP2018035138A5 (https=) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| JP2010516229A5 (https=) | ||
| JP2015534982A5 (https=) | ||
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| JP2012532851A5 (https=) | ||
| JP2022525377A5 (https=) |